您要查找的是不是：
- OBJECTIVEA method for the determination of dissolution of fenofibrate chewable tablets in vitro was established. 目的:建立非诺贝特咀嚼片体外溶出度试验测定方法。
- Fenofibrate obviously inhibited PAI-1 mRNA expression in adipose tissue(P<0.01). 非诺贝特治疗后脂肪组织PAI-1mRNA表达明显低于高胆固醇组(P<0.;01)。
- The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo. 初次截肢的风险非诺贝特组较安慰剂组降低了36%25。
- Objective: To study the effects of Provastatin with Micronized Fenofibrate on HDL C and LDL C in old patients. 目的:研究普伐他汀和微粒化非诺贝特对老年人高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)的作用。
- Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. 非诺贝特显著降低HDL胆固醇水平较低患者或高血压患者的CVD事件。
- CONCLUSION:micronised fenofibrate is bene ficial on adjusting lipid level and blood viscosity. 结论：微粒化非诺贝特能有效降低高血脂，同时明显改善了病人的高粘血症。
- Methods: 49 elderly patients with hyperlipoproteinemia were randomly divided into two groups: 27 in Provastatin group;22 in Fenofibrate group. 方法:49例混合型高血脂的老年患者随机分成两组,27例服用普伐他汀,22例服用微粒化非诺贝特。
- Pravastatin, simvastatin, atorvastatin, fluvastatin, gemfibrozil and fenofibrate had a confirmed effect in secondary prevention. 吉非贝齐一级预防虽降低心血管的死亡率,但不降低总死亡率;
- To study the effects ofmicronised fenofibrate on serum lipid level and hemorheologic changes in patientswith primary hyperli pidemia. 目的：观察微粒化非诺贝特的降血脂疗效及是否有改善血液流变性的作用。
- For hypertension and hyperlipidaemia consider the use of losartan and fenofibrate, respectively (both have modest uricosuric effects). 对于有高血压和高脂血症患者可分别考虑用氯沙坦和非诺贝特（两者均有一定促进尿酸排泄的作用）。
- The study found virtually no difference in the risk for amputations above the ankle between those who did and did not take fenofibrate. 研究发现踝以上截肢风险在服用非诺贝特组和非服用非诺贝特组之间并无显著差异。
- Objective To research the effect of different serum lipid adjustment drugs, Simvastatin and Fenofibrate, on hyperlipidemic fatty liver. 目的探讨不同作用机制的调脂药（非诺贝特和辛伐他汀）对高脂血症性脂肪肝的作用。
- The fenofibrate micronized powders were prepared using lactose and MCC as the main expicients for preparation of fenofibrate tablets. 以乳糖和微晶纤维素作为主要辅料制备非诺贝特的微粉化物,并以此制备片剂,辅以预胶化淀粉调节片剂的溶出度。
- The study included 9,795 people, ages 50 to 75, who took either 200 milligrams of fenofibrate or a placebo daily for five years. 该研究样本为9，795人，年龄50至75岁，每天服用200毫克非诺贝特或安慰剂，持续五年。
- Methods 32 male New Zealand white rabbits were divided into fenofibrate group one(50 ?/?/d), fenofibrate group two(25 ?/?/d)and control group, there were 8 rabbits in each groups. 方法 将 32 只雄性新西兰白兔随机分为非诺贝特 1 组(50 ?/?/d)、非诺贝特 2 组(25 ?/?/d)、阿托伐他汀组(5 ?/?/d)及对照组,每组各 8 只。
- Similarly, fenofibrate and the combination (but not simvastatin) significantly increased the percentage of buoyant LDL cholesterol constituting total LDL cholesterol. 类似的，非诺贝特和联合治疗显著升高有浮力的LDL在总LDL中的比例。
- The study also found that people in the fenofibrate group had a 47 percent lower risk of amputations below the ankle and without large-vessel disease in the amputated limb. 研究还发现非诺贝特组踝以下截肢风险降低47%25，所截肢内其无大血管病变。
- Objective To investigate the effects of micronized fenofibrate on low density lipoprotein (LDL) subfraction profiles in type IV hyperlipidemic subjects. 目的观察微粒化非诺贝特对IV型高脂血症患者血清低密度脂蛋白（LDL）亚组份再分布的作用。
- Combination therapy reduced dense VLDL cholesterol significantly more than did fenofibrate or simvastatin monotherapy, the investigators found. Simvastatin lowered intermediate density lipoprotein (IDL) cholesterol significantly more than did fenofibrate. 研究者发现，联合治疗相对于但用非诺贝特或辛伐他汀显著的降低极低密度脂蛋白胆固醇的密度。辛伐他汀比非诺贝特降低中等密度脂蛋白胆固醇的作用显著。
- Fenofibrate 20 mg/kg was given daily to the treated group. OGTT was performed at the age of 8,16 and 24 wks. Blood glucose,serum lipids and 24 h urine albumin excretion(UA) were investigated. 每日分别以20 mg/kg的非诺贝特及等量的蒸馏水灌胃,8、16、24周行OGTT,测定血糖、血脂及24 h尿白蛋白(24 h UAlb)。
